Nanomedicine for glioblastoma: Progress and future prospects

Khan, Imran; Baig, Mohammad Hassan; Mahfooz, Sadaf; Imran, Mohammad; Khan, Mohd Imran; Dong, Jae-June; Cho, Jae Yong; Hatiboğlu, Mustafa Aziz

doi:10.1016/j.semcancer.2022.06.007

Cited by 27 publications

(17 citation statements)

References 242 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tight junction proteins like claudin-3 and occludin are frequently downregulated, further disrupting the barrier. Additionally, loss of pericytes, astrocyte endfeet connections, and neuronal connections could alter the BBTB microenvironment. BBTB permeability is also impacted by invading glioma cells that can physically displace astrocytic endfeet.…”

Section: Abnormal Bbb Structure In Cns Diseasesmentioning

confidence: 99%

Functionalized Nanomaterials Capable of Crossing the Blood–Brain Barrier

Zha,

Liu,

et al. 2024

ACS Nano

View full text Add to dashboard Cite

The blood−brain barrier (BBB) is a specialized semipermeable structure that highly regulates exchanges between the central nervous system parenchyma and blood vessels. Thus, the BBB also prevents the passage of various forms of therapeutic agents, nanocarriers, and their cargos. Recently, many multidisciplinary studies focus on developing cargo-loaded nanoparticles (NPs) to overcome these challenges, which are emerging as safe and effective vehicles in neurotheranostics. In this Review, first we introduce the anatomical structure and physiological functions of the BBB. Second, we present the endogenous and exogenous transport mechanisms by which NPs cross the BBB. We report various forms of nanomaterials, carriers, and their cargos, with their detailed BBB uptake and permeability characteristics. Third, we describe the effect of regulating the size, shape, charge, and surface ligands of NPs that affect their BBB permeability, which can be exploited to enhance and promote neurotheranostics. We classify typical functionalized nanomaterials developed for BBB crossing. Fourth, we provide a comprehensive review of the recent progress in developing functional polymeric nanomaterials for applications in multimodal bioimaging, therapeutics, and drug delivery. Finally, we conclude by discussing existing challenges, directions, and future perspectives in employing functionalized nanomaterials for BBB crossing.

show abstract

Section: Abnormal Bbb Structure In Cns Diseasesmentioning

confidence: 99%

Functionalized Nanomaterials Capable of Crossing the Blood–Brain Barrier

Zha,

Liu,

et al. 2024

ACS Nano

View full text Add to dashboard Cite

show abstract

“…Regrettably, even following surgery and concomitant radio/chemotherapy, the median survival time for patients is only approximately 16 months [26]. Evidently, the current approach is hindered by several limitations, which render long-term success unlikely.…”

Section: Gbm Current Therapy and Limitationsmentioning

confidence: 99%

Recent Advancements on the Use of Exosomes as Drug Carriers for the Treatment of Glioblastoma

Galardi

Bethlen

Paolo

et al. 2023

Life

View full text Add to dashboard Cite

Glioblastoma (GBM) is the most common and aggressive cancer of the brain. Presently, GBM patients have a poor prognosis, and therapy primarily aims to extend the life expectancy of affected patients. The current treatment of GBM in adult cases and high-grade gliomas in the pediatric population involves a multimodal approach that includes surgical resection followed by simultaneous chemo/radiotherapy. Exosomes are nanoparticles that transport proteins and nucleic acids and play a crucial role in mediating intercellular communication. Recent evidence suggests that these microvesicles may be used as biological carriers and offer significant advantages in targeted therapy. Due to their inherent cell-targeting properties, circulation stability, and biocompatibility, exosomes are emerging as promising new carriers for drugs and biotherapeutics. Furthermore, these nanovesicles are a repository of potential diagnostic and prognostic markers. In this review, we focus on the therapeutic potentials of exosomes in nano-delivery and describe the latest evidence of their use as a therapeutic tool in GBM.

show abstract

“…Advances in nanomedicine including nanodrug delivery systems (NDDS) hold immense potential to revolutionize the delivery of therapeutics to tumors. , To date, few NDDS can penetrate BBB/BBTB effectively and safely. , Mesoporous silica nanoparticles (MSN) have great potential as drug delivery systems due to their unique physical/chemical properties, such as large pore volume, chemical/thermal stability, high loading capacity, adjustable surface properties, and excellent biocompatibility. − Notably, it has been reported that surface-modified silica nanoparticles can penetrate BBB very well. − Leveraging this knowledge, our study employs a carefully optimized surface modification strategy on MSNs, designed to enhance BBB penetration and tumor targeting via the enhanced permeability and retention (EPR) effect, an approach validated by our previous research to significantly improve drug delivery to brain tumors . In this report, we demonstrate the efficacy of an MSN carrier loaded with the FDA-approved cancer drug docetaxel (DTX), for the treatment of TMZ-resistant brain tumors in a mouse model.…”

Section: Introductionmentioning

confidence: 99%

Overcoming the Blood–Brain Tumor Barrier with Docetaxel-Loaded Mesoporous Silica Nanoparticles for Treatment of Temozolomide-Resistant Glioblastoma

Hsu,

Chen,

Zhang

et al. 2024

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

While temozolomide (TMZ) has been a cornerstone in the treatment of newly diagnosed glioblastoma (GBM), a significant challenge has been the emergence of resistance to TMZ, which compromises its clinical benefits. Additionally, the nonspecificity of TMZ can lead to detrimental side effects. Although TMZ is capable of penetrating the blood−brain barrier (BBB), our research addresses the need for targeted therapy to circumvent resistance mechanisms and reduce off-target effects. This study introduces the use of PEGylated mesoporous silica nanoparticles (MSN) with octyl group modifications (C8-MSN) as a nanocarrier system for the delivery of docetaxel (DTX), providing a novel approach for treating TMZ-resistant GBM. Our findings reveal that C8-MSN is biocompatible in vitro, and DTX@C8-MSN shows no hemolytic activity at therapeutic concentrations, maintaining efficacy against GBM cells. Crucially, in vivo imaging demonstrates preferential accumulation of C8-MSN within the tumor region, suggesting enhanced permeability across the blood−brain tumor barrier (BBTB). When administered to orthotopic glioma mouse models, DTX@C8-MSN notably prolongs survival by over 50%, significantly reduces tumor volume, and decreases side effects compared to free DTX, indicating a targeted and effective approach to treatment. The apoptotic pathways activated by DTX@C8-MSN, evidenced by the increased levels of cleaved caspase-3 and PARP, point to a potent therapeutic mechanism. Collectively, the results advocate DTX@C8-MSN as a promising candidate for targeted therapy in TMZ-resistant GBM, optimizing drug delivery and bioavailability to overcome current therapeutic limitations.

show abstract

Nanomedicine for glioblastoma: Progress and future prospects

Cited by 27 publications

References 242 publications

Functionalized Nanomaterials Capable of Crossing the Blood–Brain Barrier

Functionalized Nanomaterials Capable of Crossing the Blood–Brain Barrier

Recent Advancements on the Use of Exosomes as Drug Carriers for the Treatment of Glioblastoma

Overcoming the Blood–Brain Tumor Barrier with Docetaxel-Loaded Mesoporous Silica Nanoparticles for Treatment of Temozolomide-Resistant Glioblastoma

Contact Info

Product

Resources

About